ABSTRACT
BACKGROUND:The introduction of erythropoietin has transformed the management of anaemia in CKD, with considerable benefits which includes enhanced quality of life, increased exercise capacity and improved cardiac function. There is paucity of data on the beneficial effects of this treatment from this environment.OBJECTIVE:The aim of this work was to study the pattern and response of anaemia and its response to treatment with recombinant human erythropoietin(r-HuEpo) in CKD patients in Nigeria. METHODS:This was a prospective study in which 20 CKD patients who satisfied the inclusion criteria were recruited consecutively. Subcutaneous r-HuEpo was administered to each of the study patients, starting with a weekly dose of 50 iu per kg and titrated according to haemoglobin (Hb) response, which was monitored fortnightly throughout the study period with the aim of achieving a target Hb of 11g per dl.RESULTS:The patients studied were anaemic with mean Hb of 7.36(1.05) g/dl. The anemia was normocytic normochromic in 85% of the patients. All the patients responded to treatment with r-HuEpo with the mean Hb rising from 6.74(0.70)g per dl to 11.64(0.37) g/dl and 7.64(1.19) to 11.98(0.45) g/dl in those on maintenance haemodialysis and pre-dialysis patients respectively. The patients reached the target Hb of 11g/dl within 8 weeks in predialytic CKD patients and within 10 weeks in those on maintenance haemodialysis.CONCLUSION: Anaemia is mostly normocytic normochromic in CKD patients in our environment and r-HuEpo therapy is effective in correcting the anaemia
Subject(s)
Anemia/drug therapy , Anemia/etiology , Erythropoietin/therapeutic use , Hematinics/therapeutic use , Nigeria , Prospective Studies , Recombinant Proteins , Renal Insufficiency, Chronic/complicationsABSTRACT
Dans une etude prospective effectuee sur 102 patients; tous drepanocytaires homozygotes en crise vaso-occlusive; l'administration concomitante du Nootropil a la dose de 100 mg/kg par voie intraveineuse directe lente; et du Voltarene a la dose de 3 mg/kg par voie intramusculaire profonde; a permis d'obtenir un amendement rapide et efficace des douleurs. Le temps moyen necessaire pour obtenir une remission totale des phenomenes hyperalgiques est de 23;1 minutes; avec un point de depart du decompte; le moment de l'injection de deux produits. Cette association tres synergique permet donc d'ameliorer; d'une facon tres remarquable et tres spectaculaire; la prise en charge des sickleniques en crise vaso-occlusive; et autorise un lever precoce des malades
Subject(s)
Anemia , Anemia/complications , Anemia/drug therapy , Drug Therapy , Psychotropic DrugsABSTRACT
Vingt six sujets drepanocytaires homozygotes porteurs d'une rate volumineuse ont ete traites avec le Piracetam associe a la Quinine administres par voie orale pendant 35 semaines. Au terme de cet essai therapeutique; 21 cas; soit 81 pour cent ont connu une regression remarquable; voire une disparition de la splenomegalie; contre 5 cas d'echec; soit 19 pour cent. Les meilleurs resultats sont obtenus au cours des 16 premieres semaines du traitement et se traduisent par un Index Moyen de Regression de la splenomegalie (I.M.R.S.) tres significatif; variant de 0;75 a 3;3
Subject(s)
Anemia , Anemia/drug therapy , Splenomegaly/drug therapy , Tropical MedicineABSTRACT
Le profil de variation de deux proteines de la reaction inflammatoire : la proteine C-reactive (CRP) et l'a1-glycoproteine acide a1-GPA ou orosomucoide et de la transferrine(TF) a ete etudie; afin d'evaluer leur interet clinique et/ou pronostique; au cours de la crise vasculo-occlusive de la drepanocytose homozygote; traitee et non traitee. Cet ensemble de parametres biochimiques devrait alors faire partie de tout bilan de la drepanocytose et constituerait ainsi un mini-profil proteique de surveillance et du traitement de la maladie drepanocytaire
Subject(s)
Anemia , Anemia/complications , Anemia/diagnosis , Anemia/drug therapy , Anemia/prevention & control , Anti-Inflammatory Agents , C-Reactive Protein , Glycoproteins , Orosomucoid , TransferrinABSTRACT
Twenty pregnant women who had been given total dose infusion (TDI) of iron dextran at Muhimbili Medical Centre; Dar es Salaam; Tanzania; had their bone marrows examined and red blood cell parameters measured. In 35 per cent of the study group there was no stainable iron in the marrow. The rest showed abnormally increased amounts of marrow iron; and in three of them there was normal in five and increased in the remainder. This increase was probably pregnancy induced